Stock UCBUCB
Add to a list
To use this feature you must be a member
Log inSign up

UCB Stock

Equities

UCB

BE0003739530

Pharmaceuticals

Market Closed - Euronext Bruxelles
Other stock markets
 18:55:00 18/07/2025 +03 		5-day change 1st Jan Change
174.85 EUR +0.49% Intraday chart for UCB +2.28% -9.03%
07-01 Alvotech, Advanz Pharma Sign Supply, Commercial Deal for Cimzia Biosimilar in Europe MT
06-27 UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency Disorder CI

Valuation: UCB

Capitalization 33.23B 38.73B 30.96B 28.81B 53.15B 3,335B 59.34B 374B 141B 1,564B 145B 142B 5,748B P/E ratio 2025 *
33.3x
P/E ratio 2026 * 24.1x
Enterprise value 33.84B 39.44B 31.53B 29.33B 54.12B 3,397B 60.43B 381B 144B 1,592B 148B 145B 5,854B EV / Sales 2025 *
5.03x
EV / Sales 2026 * 4.26x
Free-Float
61.3%
Yield 2025 *
0.81%
Yield 2026 * 0.83%
More valuation ratios * Estimated data

Chart: UCB

Dynamic Chart

Latest news: UCB

Alvotech, Advanz Pharma Sign Supply, Commercial Deal for Cimzia Biosimilar in Europe 07-01 MT
UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency Disorder 06-27 CI
UCB: share up after positive phase 3 trial 06-27Zonebourse
EU reviews risk of abuse in some treatments for alcohol dependency (June 20) 06-23 RE
Europe stocks fall on fears of Iranian retaliation after U.S. strikes 06-23 RE
Europe stocks fall on fears of Iranian retaliation after U.S. strikes 06-23 RE
Morgan Stanley Upgrades UCB to Overweight, Raises PT 06-23 MT
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity 06-12 CI
UCB Announces New Biologics Manufacturing Facility In U.S. 06-12 RE
Biogen, UCB Say Dapirolizumab Pegol Phase 3 Study Shows Improvement in Fatigue, Reduction in Disease Activity 06-12 MT
UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus 06-12 CI
UCB Says Its DZP Shows 'Efficacy' Across Multiple Clinical Endpoints 06-12 RE
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis by UCB 06-11 CI
More news

Last Transcript: UCB

Logo UCB
UCB SA, 2024 Earnings Call, Feb 27, 2025
02-27
More transcripts

Analysts' recommendations: UCB

Morgan Stanley Upgrades UCB to Overweight, Raises PT 06-23 MT
Intron Health Begins UCB's Coverage at Buy 06-11 MT
Sadif Investment Analytics Downgrades UCB to Sell 05-30 MT
UCB : UCB finally becomes affordable 04-14Alphavalue
UCB : Lower-than-expected 2025 guidance weighed on good H2 24 results 02-28Alphavalue
More recommendations

Press Releases: UCB

UCB : Transparency notification FMR LLC 07-10 PU
UCB : Transparency notification BlackRock, Inc. 07-08 PU
UCB : BIMZELX(bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden 07-08 PU
UCB : presents latest research advancements at European Pediatric Neurology Society Congress 07-08 PU
UCB : announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder 06-27 PU
More press releases

News in other languages: UCB

UCB op de kooplijst van Goldman Sachs 07-16
Prima beursdebuut voor EnergyVision in rustige beursweek 07-13
Wall Street vue dans le vert, les négociations commerciales continuent 07-09
Succesvolle IPO EnergyVision op lichtgroene beurs 07-09
Le secteur pharmaceutique européen recule après des menaces douanières de Trump 07-09
More news

Quotes and Performance

1 day+0.49%
1 week+2.28%
Current month+4.73%
1 month+12.70%
3 months+28.28%
6 months-4.19%
Current year-9.03%
More quotes

Course Extremes

1 week 168.45
Extreme 168.45
 175.7
1 month 156.8
Extreme 156.8
 175.7
Current year 129.35
Extreme 129.35
 198.95
1 year 129.35
Extreme 129.35
 198.95
3 years 65.4
Extreme 65.4
 198.95
5 years 65.4
Extreme 65.4
 198.95
10 years 54.84
Extreme 54.84
 198.95
More quotes

Managers and Directors: UCB

Manager TitleAgeSince
Jean-Christophe Tellier CEO
 Chief Executive Officer 66 01/01/2015
Sandrine Dufour DFI
 Director of Finance/CFO 58 01/07/2020
Antje Witte IRC
 Investor Relations Contact - -
Director TitleAgeSince
Charles-Antoine Janssen BRD
 Director/Board Member 54 01/01/2012
Jean-Christophe Tellier BRD
 Director/Board Member 66 01/01/2015
Jonkheer Cédric van Rijckevorsel BRD
 Director/Board Member 55 24/04/2014
More insiders

Biopharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
UCB Stock UCB
+0.49%+2.28%+27.49%+106.34% 38.73B
CSL LIMITED Stock CSL Limited
+3.62%+6.83%-17.43%-11.45% 81.33B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-1.36%-4.44%-48.99%-8.93% 57.33B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.78%+5.10%+23.65%+29.75% 53.86B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-0.06%+10.55%+118.53%+146.33% 19.4B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+0.31%+11.62%+86.31%+820.19% 18.86B
BIOGEN INC. Stock Biogen Inc.
-2.88%-6.87%-44.79%-43.25% 18.31B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
-0.04%-.--%+76.16%+135.78% 14.02B
INCYTE CORPORATION Stock Incyte Corporation
-1.57%-1.06%+3.02%-16.59% 13.14B
MODERNA, INC. Stock Moderna, Inc.
-2.92%-7.07%-74.20%-81.30% 12.09B
Average -0.62%+1.32%+14.97%+107.69% 32.71B
Weighted average by Cap. +0.11%+1.96%+4.37%+68.77%
See all sector performances

Financials

2025 *2026 *
Net sales 6.73B 7.85B 6.27B 5.84B 10.77B 676B 12.02B 75.79B 28.61B 317B 29.44B 28.83B 1,165B 7.63B 8.9B 7.11B 6.62B 12.21B 766B 13.63B 85.94B 32.44B 359B 33.38B 32.69B 1,321B
Net income 964M 1.12B 898M 835M 1.54B 96.73B 1.72B 10.85B 4.09B 45.35B 4.21B 4.13B 167B 1.37B 1.6B 1.28B 1.19B 2.2B 138B 2.45B 15.47B 5.84B 64.69B 6.01B 5.88B 238B
Net Debt 609M 710M 568M 528M 975M 61.17B 1.09B 6.86B 2.59B 28.68B 2.66B 2.61B 105B -721M -840M -672M -625M -1.15B -72.35B -1.29B -8.11B -3.06B -33.92B -3.15B -3.09B -125B
More financial data * Estimated data

Company Profile

Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,215
Sector
Pharmaceuticals
Calendar
07-31 - Q2 2025 Earnings Release
More about the company

Quotes

Date Price Change Volume
18/07/25 174.85 € +0.49% 273,526
17/07/25 174.00 € +2.56% 242,060
16/07/25 169.65 € -0.62% 223,991
15/07/25 170.70 € -1.07% 147,764
14/07/25 172.55 € +0.94% 119,357

Real-time Euronext Bruxelles, July 18, 2025 at 06:55 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
174.85EUR
Average target price
214.39EUR
Spread / Average Target
+22.61%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. UCB Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition